EMA to Revise Multiplicity Points-to-Consider Guideline
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is seeking public input as it works to update its points-to-consider document on multiplicity issues in clinical trials.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.